Drug intelligence / Profile preview

LY2959530

Development stage: Unknown
Lead developer: Neumora Therapeutics
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules

Overview

LY2959530 is a radioligand utilized in Positron Emission Tomography (PET) imaging. Developed in the context of studies sponsored by BlackThorn Therapeutics, Inc., its primary function is to measure the occupancy of the nociceptin/orphanin FQ peptide (NOP) receptor in biological systems, such as the human brain. This diagnostic tool allows researchers to assess the binding characteristics of other therapeutic agents, like LY2940094, to the NOP receptor, providing crucial data for drug development and understanding receptor pharmacology.

Targets

NOP (Nociceptin/orphanin FQ peptide receptor)

Beyond the preview

Go deeper on LY2959530.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY2959530.

Explore the full profile